LH Stock Chart & Stats
$4705.14
$0.00(0.00%)
At close: 4:00 PM EDT
$4705.14
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,000.00 - $7,088.39
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
$550.62B
Enterprise Value$31.67B
Total Cash (Recent Filing)$261.80M
Total Debt (Recent Filing)$6.78B
Price to Earnings (P/E)29.5
Beta0.11
Next Earnings
Feb 11, 2027EPS Estimate
85.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.27
Shares Outstanding81,100,000
10 Day Avg. Volume6
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)2.42
Price to Sales (P/S)1.50
P/FCF Ratio17.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7,182.78Price Target Upside52.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)348.47
Revenue Forecast (FY)$279.70B
Bulls Say, Bears Say
Bulls Say
Broad-based Growth And Margin ExpansionGrowth is broad enough to support durable operating improvement rather than relying on a single product or customer. Revenue expansion combined with higher margins indicates operating leverage and productivity benefits, strengthening the company’s ability to grow earnings and cash flow over the next several quarters.
Biopharma Laboratory BacklogThe large BLS backlog provides meaningful visibility into future revenue conversion and supports the durability of the drug-development services franchise. Strong book-to-bill and double-digit organic growth also indicate sustained demand from biopharma customers, while expanded laboratory capacity can support continued execution.
Specialty Diagnostics And InnovationFaster specialty-testing growth can improve Labcorp’s mix and deepen physician relationships because specialty orders often generate additional core laboratory testing. FDA-cleared and approved offerings in oncology, neurology, and precision medicine broaden the company’s differentiated platform and support longer-term relevance.
Bears Say
PAMA Reimbursement PressureThe proposed reimbursement reductions represent a structural pressure on the diagnostics business rather than a temporary fluctuation. Lower Medicare and Medicaid rates could compress revenue and margins across multiple years, requiring productivity savings, growth, and mix improvement to preserve the company’s earnings trajectory.
Meaningful LeverageAlthough leverage has improved from 2024–2025, the debt load remains a meaningful fixed obligation relative to equity. This reduces balance-sheet flexibility and makes sustained earnings and cash generation important for continued deleveraging, acquisitions, capital returns, and resilience if operating conditions weaken.
Moderate Cash Conversion And Below-peak MarginsLabcorp generates substantial absolute cash, but cash conversion is not fully keeping pace with reported earnings, limiting internal funding efficiency. Profitability has recovered from 2023 yet remains below prior peaks, so additional execution is needed before the business can demonstrate fully restored margin durability.
Labcorp Holdings News
LH FAQ
What was Labcorp Holdings’s price range in the past 12 months?
Labcorp Holdings lowest stock price was $3000.00 and its highest was $7088.39 in the past 12 months.
What is Labcorp Holdings’s market cap?
Labcorp Holdings’s market cap is $550.62B.
When is Labcorp Holdings’s upcoming earnings report date?
Labcorp Holdings’s upcoming earnings report date is Feb 11, 2027 which is in 102 days.
How were Labcorp Holdings’s earnings last quarter?
Labcorp Holdings released its earnings results on Oct 28, 2026. The company reported $90.257 earnings per share for the quarter, beating the consensus estimate of $87.689 by $2.568.
Is Labcorp Holdings overvalued?
According to Wall Street analysts Labcorp Holdings’s price is currently Undervalued.
Does Labcorp Holdings pay dividends?
Labcorp Holdings does not currently pay dividends.
What is Labcorp Holdings’s EPS estimate?
Labcorp Holdings’s EPS estimate is 85.16.
How many shares outstanding does Labcorp Holdings have?
Labcorp Holdings has 81,100,000 shares outstanding.
What happened to Labcorp Holdings’s price movement after its last earnings report?
Labcorp Holdings reported an EPS of $90.257 in its last earnings report, beating expectations of $87.689. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Labcorp Holdings?
Currently, no hedge funds are holding shares in MX:LH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Labcorp Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7,182.78 (52.66% Upside)
$7,182.78 (52.66% Upside)
Blogger Sentiment
Neutral
MX:LH Sentiment 67%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $13.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.66%
12-Months-Change
Fundamentals
Return on Equity
11.54%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Labcorp Holdings
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
LH Company Deck
LH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. LabCorp reported broad-based revenue growth, margin expansion, 14.5% adjusted EPS growth, higher 2026 guidance, strong diagnostics and biopharma laboratory demand, a robust backlog, and multiple specialty testing and acquisition opportunities. The principal negative issue was the proposed PAMA reimbursement reduction and its estimated $125 million 2027 impact, along with smaller ACA and foreign exchange headwinds. Management emphasized multiple stated offsets, including organic growth, BLS momentum, Launchpad savings, and business development, so the highlights significantly outweighed the lowlights.View all MX:LH earnings summariesLH Revenue Breakdown
77.96% Dx
22.21% BLS
-0.16% Intercompany eliminations
LH Stock 12 Month Forecast
Average Price Target
$7,182.78
▲(52.66% Upside)